Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 6

See more details

Referenced in 7 patents
93 readers on Mendeley
  • Article usage
  • Citations to this article (346)

Advertisement

Research Article Free access | 10.1172/JCI115442

Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin.

W C Darbonne, G C Rice, M A Mohler, T Apple, C A Hébert, A J Valente, and J B Baker

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

Find articles by Darbonne, W. in: PubMed | Google Scholar

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

Find articles by Rice, G. in: PubMed | Google Scholar

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

Find articles by Mohler, M. in: PubMed | Google Scholar

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

Find articles by Apple, T. in: PubMed | Google Scholar

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

Find articles by Hébert, C. in: PubMed | Google Scholar

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

Find articles by Valente, A. in: PubMed | Google Scholar

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

Find articles by Baker, J. in: PubMed | Google Scholar

Published October 1, 1991 - More info

Published in Volume 88, Issue 4 on October 1, 1991
J Clin Invest. 1991;88(4):1362–1369. https://doi.org/10.1172/JCI115442.
© 1991 The American Society for Clinical Investigation
Published October 1, 1991 - Version history
View PDF
Abstract

IL-8 (also known as neutrophil-activating peptide 1) is recognized as a potent effector of neutrophil functions. Several different cell types that contact blood, namely T lymphocytes, monocytes, and endothelial cells, secrete this polypeptide following stimulation by cytokines, or lipopolysaccharide. Here we show that when IL-8 is added to blood it rapidly partitions from the plasma fluid to the blood cells and that erythrocytes account for the vast majority of this binding. Analysis of 125I-IL-8 binding [( ala-IL-8]77 form) to human red cells indicates a single, 5 nM Kd affinity class of binding sites, present at approximately 2,000 per red cell representing approximately 15 nmol of red cell IL-8 binding sites per liter of blood. These sites are protease sensitive. Their binding of IL-8 is rapidly reversible and does not result in receptor internalization, although bound IL-8 is resistant to extraction by pH 3 buffer at 5 degrees C. 125I-IL-8 binding to red cells was not inhibited by epidermal growth factor or interleukin 1, but was inhibited by monocyte chemotactic peptide-1, which is not a neutrophil chemotaxin, but is a member of the same family of polypeptides as IL-8. FACS analysis of IL-8-mediated mobilization of Ca2+ in neutrophils indicates that the IL-8 bound to red cells is incapable of stimulating neutrophils. Thus, red cell absorption of IL-8 may function to limit stimulation of leukocytes by IL-8 released into blood.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1362
page 1362
icon of scanned page 1363
page 1363
icon of scanned page 1364
page 1364
icon of scanned page 1365
page 1365
icon of scanned page 1366
page 1366
icon of scanned page 1367
page 1367
icon of scanned page 1368
page 1368
icon of scanned page 1369
page 1369
Version history
  • Version 1 (October 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 6
  • Article usage
  • Citations to this article (346)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 7 patents
93 readers on Mendeley
See more details